Cargando…
Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication
Chronic activation of the immune system in HIV infection is one of the strongest predictors of morbidity and mortality. As such, approaches that reduce immune activation have received considerable interest. Previously, we demonstrated that administration of a type I interferon receptor antagonist (I...
Autores principales: | Nganou-Makamdop, Krystelle, Billingsley, James M., Yaffe, Zachary, O’Connor, Gregory, Tharp, Gregory K., Ransier, Amy, Laboune, Farida, Matus-Nicodemos, Rodrigo, Lerner, Andrea, Gharu, Lavina, Robertson, Jennifer M., Ford, Mandy L., Schlapschy, Martin, Kuhn, Nadine, Lensch, Alexandra, Lifson, Jeffrey, Nason, Martha, Skerra, Arne, Schreiber, Gideon, Bosinger, Steven E., Douek, Daniel C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126880/ https://www.ncbi.nlm.nih.gov/pubmed/30142226 http://dx.doi.org/10.1371/journal.ppat.1007246 |
Ejemplares similares
-
Manipulating the Interferon Signaling Pathway: Implications for HIV Infection
por: Nganou-Makamdop, Krystelle, et al.
Publicado: (2019) -
PASylation: a biological alternative to PEGylation for extending the
plasma half-life of pharmaceutically active proteins
por: Schlapschy, Martin, et al.
Publicado: (2013) -
High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation
por: Mendler, Claudia T, et al.
Publicado: (2014) -
PASylated Thymosin α1: A Long-Acting Immunostimulatory Peptide for Applications in Oncology and Virology
por: Binder, Uli, et al.
Publicado: (2020) -
First In-Human Medical Imaging with a PASylated (89)Zr-Labeled Anti-HER2 Fab-Fragment in a Patient with Metastatic Breast Cancer
por: Richter, Antonia, et al.
Publicado: (2020)